Concerns raised by the Pharmacists’ Division of the Association of Professional
Engineers, Scientists and Managers, Australia over employees being ‘left out’ of
negotiations for the Fifth Community Pharmacy Agreement were unfounded, the
Pharmaceutical Society of Australia said today.

President of the PSA, Warwick Plunkett, said the concerns were raised to stimulate a
response from employee pharmacists on issues to be discussed in the CPA
negotiations.

“But these comments are well off target and display a lack of understanding of the CPA
process and other initiatives seeking to promote pharmacists’ expertise in delivering
health policy priorities,” Mr Plunkett said.

“The Community Pharmacy Agreement is only about community pharmacy-based
services and their remuneration.
“Services that should be funded by government and delivered outside of community
pharmacy need to be the subject of a separate agreement with the profession.”
Mr Plunkett said the PSA, with a membership covering 75 per cent of all practicing
pharmacists including employers and employees, was well represented in the
negotiating process and was well placed to look after the interests of employee
pharmacists in the CPA.

“Of course PSA would welcome any direct ideas or comments from all parts of its
membership to guide it on stances to be taken during the negotiations,” he said.
Responding to APESMA concerns over the future direction of pharmacy, Mr Plunkett
said: “PSA agrees that Government should be, and no doubt is, having dialogue with
the other major pharmacy organisations on issues affecting the profession but not on
those issues relevant to CPA.

“The future direction of Pharmacy is the subject of a Green and White Paper process
recently initiated by PSA and which will include input from all sectors of pharmacy
during its development.

“Professional services relating to Primary Health Care and Preventive Health Care
delivery by community pharmacies will be put forward in the negotiations for CPA5 but
could be subject to attracting funding and support from other areas.”

Source
Pharmaceutical Society of Australia

Boston Scientific Corporation (NYSE: BSX) announced it has received approval from the U.S. fda.gov/” rel=”nofollow”>Food and Drug Administration (FDA) to market its TAXUS((R)) Liberte((R)) Long Paclitaxel-Eluting Coronary Stent System, a next-generation drug-eluting stent (DES) designed for long lesions. At 38 mm, it is the longest available DES, providing doctors an option that can potentially reduce the number of stents used in more complex cases, simplifying procedures and reducing costs. It affords a more efficient treatment option for the estimated 8 to 10 percent(1) of patients with long lesions. The Company plans to launch the product in the U.S. next month. It received CE Mark approval in 2007.

“The TAXUS Liberte Long Stent offers physicians and patients distinct advantages compared to using two overlapping drug-eluting stents,” said Mark Turco, M.D., FACC, FSCAI, Director of the Center for Cardiac & Vascular Research at Washington Adventist Hospital, Takoma Park, Maryland. “In the ATLAS Long Lesion Trial, the 38 mm TAXUS Liberte Stent significantly reduced myocardial infarction when compared to the TAXUS((R)) Express((R)) Stent, making the TAXUS Liberte Long Stent an attractive option for interventional cardiologists faced with long, challenging lesions.”

The TAXUS ATLAS Long Lesion Trial reported a significant 79 percent reduction in the rate of nine-month myocardial infarction for the TAXUS Liberte Long Stent as compared to the TAXUS Express Stent control (1.3% vs. 6.3%, p=0.026). At two years, the composite measure of cardiac death or myocardial infarction showed a significant 63 percent reduction for the TAXUS Liberte Long Stent compared to the TAXUS Express Stent (3.5% vs. 9.4%, p=0.0426). The rate of stent thrombosis at two years was zero percent for the TAXUS Liberte Long Stent and 0.8 percent for the TAXUS Express Stent(2).

“Today’s announcement is the latest example of the breadth of our market-leading drug-eluting stent portfolio,” said Hank Kucheman, Senior Vice President and Group President, Cardiovascular for Boston Scientific. “The TAXUS Liberte Long Stent and our TAXUS Liberte Atom((TM)) Stent — approved by the FDA in May for use in small vessels — are key differentiators. No other company offers a 38 mm length or 2.25 mm diameter DES. Our ongoing leadership is due not only to the range and quality of our products but also to the success of our two-drug strategy, giving physicians the choice of both paclitaxel- and everolimus-based DES.”

Boston Scientific has the industry’s widest range of coronary stent sizes. The TAXUS Liberte Stent Series is now available in 92 sizes, ranging from 2.25 mm to 4.0 mm in diameter and from 8 mm to 38 mm in length.

TAXUS Stents have been evaluated by the industry’s most extensive randomized, controlled clinical trial program, with follow-up to five years in some cases. These trial results have been supplemented by data on more than 35,000 patients enrolled in post-approval registries. To date, approximately 11 million Boston Scientific stents have been implanted globally, making them the world’s most frequently used stents.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding regulatory approvals, clinical trials, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

(1) Percentage estimates from April 2009 Millennium Research Group report and ARRIVE 1 and 2 registries.

(2) In the TAXUS ALTAS Long Lesion Trial, the TAXUS Liberte Long (38mm) Stent met its primary endpoint of non-inferiority to the TAXUS Express control Stent in nine-month percent diameter stenosis (31.7% vs. 32.6%, p=0.71) and reported a 36 percent reduction in MACE (9.4% vs. 14.8%, p=0.16).

Source: Boston Scientific Corporation

A clinical study published in the journal Phytotherapy Research found that GlucAffect, a nutritional supplement developed by Reliv International, Inc. (Nasdaq: RELV), significantly reduced blood glucose levels and helped control weight in study participants.

The study included 50 overweight individuals who had pre-diabetic glucose levels prior to the study. Subjects taking GlucAffect, a powdered product mixed with water or other liquids, lowered their fasting blood glucose by an average of 30 percent and they lost an average of 16 pounds. Subjects in the control group reported a marginal decline in blood glucose levels and no significant weight loss.

The study was conducted at Gabriele D’Annunzio University in Chieti-Pescara, Italy.

“The people in the GlucAffect group achieved statistically significant lower blood sugar levels as well as significant weight loss compared to both their own baseline starting point and to the results of the people in the placebo group,” said Dr. Carl Hastings, Reliv’s vice chairman and chief scientific officer, who is a Ph.D. in food science. “GlucAffect enabled subjects to achieve healthy weight and blood sugar levels after eight weeks,” Hastings added.

Elevated weight and blood glucose levels are key factors in metabolic syndrome, which dramatically increases the likelihood of developing diseases such as diabetes, heart disease and stroke. According to the American Heart Association, nearly 1 in 4 American adults have the metabolic syndrome.

The participants consumed GlucAffect or a placebo product four times a day for six days a week, participated in an exercise program and ate a healthy diet. They didn’t follow the study regimen on the seventh day of the week.

“GlucAffect is formulated with a unique combination of innovative ingredients selected to maintain healthy blood sugar levels and promote overall health,” said Hastings, who created GlucAffect and was one of the authors of the study.

Reliv will apply for a patent on GlucAffect. All Reliv products are developed, tested and manufactured at the company’s headquarters in Chesterfield, Mo.

About Reliv

Reliv International, Inc., based in Chesterfield, Mo., is a developer, manufacturer and marketer of a proprietary line of nutritional supplements. Reliv supplements address essential daily nutrition, weight loss and targeted solutions such as energy and performance enhancement, blood sugar management, digestive health and anti-aging. Reliv sells its products through an international network marketing system of approximately 68,700 independent distributors.

Source: Reliv International, Inc